Home Your basket
• Delayed labyrinthine fist...
   Price 10.50 €
• Mast cells in chronic inf...
   Price 10.50 €
• Efficacy and safety of mo...
   Price 10.50 €
• Vertebro and cranio veino...
   Price 14.00 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Tympanoplasty: Experience...
   Price 12.00 €
• A rare tumor of the parap...
   Price 5.50 €
• Usher type I syndrome in ...
   Price 10.50 €
• The symphonix symposium u...
   Price 8.50 €
• CT scan, MR imaging and a...
   Price 10.50 €
• Endoscopic endonasal surg...
   Price 8.50 €
• Rare benin tumors of the ...
   Price 5.50 €
• The relevance of Choukrou...
   Price 10.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Modern lipostructure: The...
   Price 10.50 €
• The “Deglutition Handicap...
   Price 10.50 €
• Therapeutic education of ...
   Price 12.50 €
• Congenital bilateral choa...
   Price 5.50 €
• Endoscopic medialization ...
   Price 8.50 €
• IPSEN Foundation meeting:...
   Price 5.50 €
• Benign tumors of the nasa...
   Price 14.00 €
• The cholesteatomatous rin...
   Price 5.50 €
• Ethmoid-nasal meningioma ...
   Price 10.00 €
• Laryngeal schwannomas...
   Price 5.50 €
• Can homograft ossicles st...
   Price 5.50 €
• Eagle’s syndrome: A case ...
   Price 10.50 €
• Cerebro-spinal fluid otor...
   Price 5.50 €
• Facial aesthetic lipostru...
   Price 10.50 €
• Hearing results in stapes...
   Price 10.50 €
• Metastatic melanoma to th...
   Price 5.50 €
• Autistic like behaviour d...
   Price 8.50 €
• Navigation in head and ne...
   Price 10.50 €
• Audiological comparison b...
   Price 14.00 €

Total Order 297.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 1 - 2016 o

RHINOLOGY

Efficacy of nasal irrigation with 2.2% hypertonic seawater in the treatment of chronic rhinosinusitis in adults


Authors : Strnad P, Skoupá J, HornÍk P, Cimrová H, Cerná V. (Prague)

Ref. : Rev Laryngol Otol Rhinol. 2016;137,1:3-10.

Article published in english
Downloadable PDF document english



Summary : Objective: To evaluate the efficacy and the tolerance of nasal irrigation with 2.2% hypertonic seawater in the treatment of chronic rhinosinusitis (CRS) in adults either used as mono­therapy, or in combination with intranasal corticosteroids. Method: In this prospective, open-label, multicenter controlled trial, 238 patients diagnosed with CRS were randomly assigned to three groups: group 1 with intranasal corticosteroids (steroid), group 2 with nasal irrigation with hypertonic seawater (seawater) and group 3 with a treatment combining intranasal corticosteroids at lower dose and seawater (steroid+seawater). Nasal index score (NIS), patient health status, intranasal corticosteroids intake, tolerance were assessed at baseline, week 2 and 6, and satisfaction at week 6. Results: NIS was significantly improved in group 2 (seawater) and group 3 (steroid+seawater) at week 2 (p< 0.001 in both groups) and week 6 (p< 0.0001 in both groups) compared to group 1 (steroid), along with a significant decrease of intranasal corticosteroids (p < 0.0001). Patient health status improved in group 2 and group 3 at week 2 (p= 0.1040 and p< 0.001 respectively) compa­red to control (steroid), and this improvement was significantly greater in both groups at week 6 compared to steroid group (p< 0.0001). Conclusion: Hypertonic nasal irrigation is an effective treatment for CRS in adults. It significantly improved nasal symptoms and allowed a signi­fi­cant decrease of intranasal corticosteroids use while improving patient health status. Nasal irrigation with 2.2% hypertonic seawater could therefore be considered as first-line treatment for CRS, either as monotherapy or in combination with lower dosage of intranasal corticosteroids.

Price : 15.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE